Tanzisertib is primarily used in the field of medical research and treatment, particularly in the area of oncology. It functions as a selective inhibitor of certain kinases that are involved in the regulation of cell growth and survival. This makes it a potential candidate for the treatment of various types of cancers, especially those that are driven by the dysregulation of these kinase pathways. Clinical trials are ongoing to evaluate its efficacy and safety in treating specific cancers, with a focus on its ability to inhibit tumor growth and improve patient outcomes. Additionally, Tanzisertib is being studied for its potential use in combination therapies, where it may enhance the effectiveness of other cancer treatments. Its application in these areas highlights its significance in advancing cancer therapy and providing new options for patients with limited treatment alternatives.